Table 4.
Representative clinical trials on CAR-NK cell therapy for oncology treatment
| Clinical trial No. | Phase | Estimated Enrolled Participants | Target | Source of NK cells | Malignancies | Preliminary Results |
|---|---|---|---|---|---|---|
| NCT00995137 | I | 14 | CD19 | Peripheral blood | B-AML | NA |
| NCT01974479 | I | 20 | CD19 | Peripheral blood | B-AML | Suspended |
| NCT03056339 | I/II | 37 | CD19 | Cord blood | CD19 + B cell tumors | 48.6% ORR, 1-year OS: 68%, 1-year PFS: 32% |
| NCT03383978 | I | 42 | HER-2 | NK-92 | Glioblastoma | NA |
| NCT03415100 | I | 30 | NKG2D ligands | Peripheral blood | Metastatic Solid Tumours | NA |
| NCT03656705 | I | 2 | Unknown | NK92 | NSCLC | NA |
| NCT03692663 | Early Phase I | 9 | PSMA | Unknown | mCRPC | NA |
| NCT03824964 | Early Phase I | 10 | CD19/CD22 | Unknown | R/R BCL | NA |
| NCT03692767 | Early Phase I | 9 | CD22 | Unknown | R/R BCL | NA |
| NCT03690310 | Early Phase I | 9 | CD19 | Unknown | R/R BCL | NA |
| NCT03692637 | Early Phase I | 30 | Mesothelin | Peripheral blood | EOC | NA |
| NCT04245722 | I | 98 | CD19 ± CD20 antibody (rituximab or obinutuzumab) | iPSC | R/R BCL or CLL | 1 case repored PR |
| NCT04623944 | I | 90 | NKG2D ligands | Peripheral blood | R/R AML or Myelodysplastic Syndromes | 4 CR/Cri |
| NCT05215015 | Early Phase I | 18 | CD33/CLL1 | Unknown | AML | NA |
| NCT04639739 | Early Phase I | 9 | CD19 | Unknown | NHL | NA |
| NCT03940833 | I/II | 20 | BCMA | NK92 | Multiple Myeloma | NA |
| NCT03940820 | I/II | 20 | ROBO | Unknown | Solid tumors | NA |
| NCT03941457 | I/II | 9 | ROBO1 | Unknown | Pancreatic Cancer | NA |
| NCT03383978 | I | 42 | HER2 | NK92 | Recurrent HER2-positive Glioblastoma | NA |
| NCT05336409 | I | 75 | CD19 | iPSC | Relapsed or Refractory CD19-Positive B-Cell Malignancies | NA |
| NCT04747093 | I/II | 12 | CD19 | Induced-T cell-like NK cells | Refractory B Cell Malignancies | NA |
| NCT04796675 | I | 27 | CD19 | Cord blood | AML, CLL, NHL | NA |
| NCT04887012 | I | 25 | CD19 | Peripheral blood | Refractory/Relapsed B-cell NHL | NA |
| NCT05020678 | I | 150 | CD19 | Peripheral blood | R/R NHL, CLL or B-ALL | 8 CR, 3 PD, 1 SD |
| NCT05137275 | Early Phase I | 56 | Trophoblast glycoprotein 5T4 | Unknown | Locally advanced or metastatic solid tumors | NA |
| NCT05008536 | Early Phase I | 27 | BCMA | Umbilical & Cord Blood | Relapsed and refractory MM | NA |
| NCT05247957 | I | 9 | NKG2D | Cord blood | Recurrent refractory AML | NA |
| NCT05213195 | I | 38 | NKG2D | Unknown | Refractory Metastatic Colorectal Cancer | NA |
| NCT04847466 | II | 55 | PD-L1 combined with pembrolizumab and N-803 | NK-92 | Advanced gastric or head and neck cancer | NA |
| NCT05008575 | I | 27 | CD33 | Unknown | R/R AML | 6 of 10 MRD-negative CR |
| NCT05194709 | Early Phase I | 40 | Trophoblast Glycoprotein 5T4 | Unknown | Advanced Solid Tumors | NA |
| NCT05379647 | I | 24 | CD19 + CD20 antibody (rituximab) | iPSC | R/R BCL | NA |
| NCT05182073 | I | 168 | BCMA | iPSC | MM | NA |
| NCT05110742 | I/II | 48 | CD5 | Cord Blood | Relapsed/ Refractory Hematological Malignances | NA |
| NCT05092451 | I/II | 94 | CD70 | Cord Blood | Relapse/ Refractory Hematological Malignances | NA |
| NCT05336409 | I | 75 | CD19 | iPSC | CD19-Positive B-Cell Malignancies | NA |
Data obtained from clinicaltrial.gov (Accessed on 24th March 2024)